BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS

被引：1
|
作者：
Jilg, S. [1 ]
Reidel, V. [1 ]
Mueller-Thomas, C. [1 ]
Koenig, J. [1 ]
Schauwecker, J. [2 ]
Burgkart, R. [2 ]
Hoeckendorf, U. [1 ]
Huberle, C. [1 ]
Gorka, O. [3 ]
Ruland, J. [3 ]
Kolb, H. [1 ]
Peschel, C. [1 ]
Oostendorp, R. [1 ]
Goetze, K. [1 ]
Jost, P. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 3, D-80290 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Orthoped, D-80290 Munich, Germany
[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Clin Chem, D-80290 Munich, Germany
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30028-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27
引用
收藏
页码：S12 / S12
页数：1
相关论文
共 50 条
  • [41] Expression of bcl-2- and ICE-related proteins in acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS).
    Guyotat, D
    Viallet, A
    Sabido, O
    Campos, L
    BLOOD, 1996, 88 (10) : 2250 - 2250
  • [42] Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells
    de Araujo Junior, Raimundo Fernandes
    Leitao Oliveira, Ana Luiza C. S.
    de Melo Silveira, Raniere Fagundes
    de Oliveira Rocha, Hugo Alexandre
    Cavalcanti, Pedro de Franca
    de Araujo, Aurigena Antunes
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2015, 240 (01) : 34 - 44
  • [43] Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells
    Doudican, Nicole
    Rodriguez, Adrianna
    Osman, Iman
    Orlow, Seth J.
    MOLECULAR CANCER RESEARCH, 2008, 6 (08) : 1308 - 1315
  • [44] Disruption of Bcl-2 heterodimerization by the BH3 mimetic ABT-737 restores spontaneous apoptosis and induces differentiation in high risk MDS and AML
    Ades, L.
    Boehrer, S.
    Braun, T.
    Grosjean, J.
    Fabre, C.
    Fenaux, Pierre
    Kroemer, Guido
    BLOOD, 2007, 110 (11) : 124A - 124A
  • [45] Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes
    Invernizzi, R
    Pecci, A
    Bellotti, L
    Ascari, E
    LEUKEMIA & LYMPHOMA, 2001, 42 (03) : 481 - 489
  • [46] Intensive chemotherapy for patients with high risk myelodysplastic syndromes (MDS) and acute myeloid leukemia.
    Shi, J
    Shao, ZH
    Liu, H
    Chen, GB
    Song, LY
    Zhang, YZ
    Li, K
    Fu, R
    Zhao, MF
    He, GS
    Bar, J
    Chu, YL
    Yang, TY
    BLOOD, 2002, 100 (11) : 336B - 336B
  • [47] Low-dose melphalan in patients with intermediate or high-risk myelodysplastic syndromes
    Xiao, Z.
    Liu, L.
    Qin, T.
    Xu, Z.
    LEUKEMIA RESEARCH, 2009, 33 : S136 - S136
  • [48] Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes
    Ohyashiki, JH
    Iwama, H
    Yahata, N
    Ando, K
    Hayashi, S
    Shay, JW
    Ohyashiki, K
    CLINICAL CANCER RESEARCH, 1999, 5 (05) : 1155 - 1160
  • [49] Intensive treatment in patients with high-risk myelodysplastic syndromes and secondary acute leukaemia
    Bargay, J
    Brunet, S
    Esteve, J
    Ribera, J
    Ribera, J
    Llorente, A
    Marti, J
    Sarrà, J
    Guardia, R
    Pedro, C
    Nomdedeu, B
    Sierra, J
    Besalduch, J
    BONE MARROW TRANSPLANTATION, 2004, 33 : S256 - S256
  • [50] Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes
    Raza, A
    Lisak, L
    Billmeier, J
    Pervaiz, H
    Mumtaz, M
    Gohar, S
    Wahid, K
    Galili, N
    LEUKEMIA & LYMPHOMA, 2006, 47 (03) : 433 - 440
12345